The Halcyon Team

Our Story

Halcyon was initially founded by Dr. Frank Chang, Ph.D., Dr.
George Tuszynski, Ph.D., and Dr. Solomon Luo, MD, FACS to pursue the development of novel cancer diagnostic and therapeutic applications.

Based on Dr. Chang's and Dr. George Tuszynski's inaugural discoveries at Temple University while studying biomarkers, Halcyon developed its 2-D HPLE technology to target GASP-1 specifically and for the early diagnosis and improved therapy of all cancers.

This lead to our expansion to neurological biomarkers for the early detection of Alzheimer's.
Dr. Frank Chang, PhD
Co-Founder, Chief Scientific Officer
Dr. Chang co-founded Halcyon to pursue diagnostic and therapeutic applications of the GASP-1 cancer biomarker. His efforts have led to the discovery of novel Alzheimer's biomarkers and multiple consumer product paths currently in development.
Temple University
Halcyon Diagnostics
Linkedin
Dr. George Tuszynski, PhD
Co-Founder
Dr. Tuszynski co-founded Halcyon with over decades of experience in the study of cancer biology, including a PhD from the University of Pennsylvania in Biochemistry..
Temple University, Professor of Neuroscience
NeoStrata Company
Proplex Technologies
Linkedin
Cesar Torres
Sr Research Scientist
Cesar is an experienced research scientist with a passion for developing biomedical technologies. He is the co-inventor of several novel drug delivery technologies, including a drug-eluting contact lens and sustained release injectable hydrogel.
University of Maryland
Lynthera Corporation
Linkedin
Omar Ghadry
Business Development
A serial problem-solver with over 20 years of startup, strategy consulting, and advisory experience.
Georgetown University
Halcyon Diagnostics
Lynthera Corporation
Linkedin
Dr. Solomon Luo, PhD
Board Chairman
TBD
University of Texas
Progressive Vision Institute
Linkedin

We are reimagining cancer and Alzheimer's diagnostics with a patient-first approach.